Scilex Holding Company (SCLX)
$2.88+2.86%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $24M
- Beta
- 1.72
- P/E (TTM)
- -0.04
- Short % float
- 2.28%
- Days to cover
- 5.8
- SI change
- -3.1%
- 1W
- -27.27%
- 1M
- -43.53%
- vs SPY 1W
- -27.13%
- vs SPY 1M
- -46.04%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 37
- VALUE
- 20
- GROWTH
- 24
- GARP
- 87
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC113.9%
REV YoY-
ROE189.8%
EPS YoY-
ROA-176.3%
GROSS41
OP-904
NET-1415
[VALUATION]
P/E TTM-0.04
P/E FWD7.17
SECTOR PE20.34
INDUSTRY PE10.09
P/B-0.06
P/FCF-
EV/EBITDA-0.33
EV/EBIT-
PEG0.05
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.07
ND/EBITDA-
BETA1.72
Company news
FAQ
- What is LOPJLB’s current signal on SCLX?
- LOPJLB’s latest quantitative signal on Scilex Holding Company (SCLX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SCLX in?
- Scilex Holding Company (SCLX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Scilex Holding Company (SCLX) do?
- Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition…